Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ketamine for Suicidal Ideation and Depression
NCT02037503Phase 3Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jan 2014
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in suicidal ideation, major depressive disorder (MDD), sponsored by Tel Aviv Sourasky Medical Center. Status: unknown.
02
Drugs
ketamine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02037503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037503.